Kabra K, et al. - The role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) Cancer Screening Trial was investigated to assess if the androgen receptor decreases renal cancer development. Via querying the PCLO trial, researchers identified predictor variables from the baseline questionnaire and follow-up questionnaires, specifically about the use of 5-&alpha reductase inhibitors (dutasteride or finasteride) and oral contraceptive therapy. Findings revealed no reduction in the incidence of renal cancer in association with self-reported use of finasteride or oral contraceptives.